IRIDEX (IRIX) Stock Price, News & Analysis

Company Overview

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company dedicated to the development, manufacturing and commercial distribution of innovative laser and light-based products for the treatment of glaucoma and other common retinal conditions. Headquartered in Mountain View, California, the company’s product offerings encompass both surgical and therapeutic devices that are used by ophthalmologists and retinal specialists around the world. IRIDEX’s flagship technologies include pattern scan lasers for efficient retinal photocoagulation and microPulse lasers designed for minimally invasive glaucoma therapy, reflecting its commitment to precision treatment and patient safety.

Since its founding in 1989, IRIDEX has expanded its global footprint through a combination of direct sales in the United States and strategic partnerships across Europe, Asia-Pacific, Latin America and the Middle East. The company’s robust distribution network ensures broad access to its laser platforms, handpieces, probes and consumables, while its field-based clinical specialists offer in‐depth training and support to eye care professionals. IRIDEX also invests in ongoing clinical research and publication initiatives to validate clinical outcomes, further reinforcing its reputation as a trusted partner for advancing ophthalmic care.

The IRIDEX product portfolio serves a diverse range of ocular indications, from the management of diabetic retinopathy and macular edema to the treatment of open-angle and neovascular glaucoma. Its patented microPulse® technology delivers energy in short pulses, reducing thermal damage to surrounding tissue and improving patient comfort. Complementing its laser platforms are diagnostic accessories and software that enable practitioners to accurately target treatment zones and monitor laser performance, underscoring the company’s end-to-end approach to clinical workflow.

Guided by an experienced executive leadership team, IRIDEX continues to innovate in response to evolving clinical needs and regulatory standards. The company maintains a dedicated research and development hub in Mountain View, while its manufacturing facility in California adheres to stringent quality management systems. Through a strategic focus on product enhancement, clinical collaboration and geographic expansion, IRIDEX aims to strengthen its position as a leader in ophthalmic laser therapies and to support clinicians in improving outcomes for patients worldwide.

Key Stats

• Today's Range: $1.25 to $1.48
• 50-Day Range: $0.88 to $1.29
• 52-Week Range: $0.78 to $2.14
• Volume: 413,025 shs
• Average Volume: 57,227 shs
• Market Capitalization: $21.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IRIDEX Stock Analysis - MarketRank™

IRIDEX scored higher than 22% of companies evaluated by MarketBeat, and ranked 573rd out of 666 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for IRIDEX.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of IRIDEX is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IRIDEX is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IRIDEX has a P/B Ratio of 9.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.63% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in IRIDEX has recently decreased by 5.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IRIDEX does not currently pay a dividend.

Dividend Growth

IRIDEX does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.63% of the float of IRIDEX has been sold short.

Short Interest Ratio / Days to Cover

IRIDEX has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in IRIDEX has recently decreased by 5.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

IRIDEX has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Computer and Technology companies.

MarketBeat Follows

2 people have added IRIDEX to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, IRIDEX insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,657.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 7.40% of the stock of IRIDEX is held by insiders.

Percentage Held by Institutions

Only 20.10% of the stock of IRIDEX is held by institutions.

IRIX Stock Analysis - Frequently Asked Questions

How have IRIX shares performed this year?

IRIDEX's stock was trading at $1.68 at the beginning of the year. Since then, IRIX shares have decreased by 25.0% and is now trading at $1.26.

How were IRIDEX's earnings last quarter?

IRIDEX Corporation (NASDAQ:IRIX) posted its quarterly earnings results on Tuesday, May, 13th. The medical equipment provider reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). The medical equipment provider had revenue of $11.90 million for the quarter, compared to analyst estimates of $12.10 million. IRIDEX had a negative trailing twelve-month return on equity of 290.57% and a negative net margin of 14.61%.
Read the conference call transcript.

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IRIDEX investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: LASERS - SYS/COMP
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRIX
• CIK: 1006045
• Web: www.iridex.com
• Phone: (650) 940-4700
• Fax: 650-940-4710
• Employees: 120
• Year Founded: 1989

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.91 million
• Net Margins: -14.61%
• Pretax Margin: -14.53%
• Return on Equity: -290.57%
• Return on Assets: -22.86%

Debt

• Debt-to-Equity Ratio: 4.28
• Current Ratio: 1.95
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $48.80 million
• Price / Sales: 0.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 9.92

Miscellaneous

• Outstanding Shares: 16,789,000
• Free Float: 15,547,000
• Market Cap: $21.66 million
• Optionable: Optionable
• Beta: 0.57